Aktienanalyse zu Aclaris Therapeutics, Inc. (ACRS)ACRSAclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aclaris Therapeutics Inc is a good buy right now due to its current price of $3.28, which is significantly below analyst price targets of $10 and $13. The RSI is at 24.444, indicating that the stock is oversold, suggesting a potential rebound. Additionally, the company has a strong cash position of $170.6 million, which can support its upcoming clinical trials, providing a solid foundation for future growth. However, the main risk is the ongoing net losses, which reached $21.5 million in Q2 2026, indicating financial strain that could affect investor confidence.

6 analysts cover ACRS: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.33.